What is Bicycle?
Bicycle Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering a new class of medicines utilizing bicyclic peptides. These fully synthetic molecules are engineered for exceptional target specificity and binding affinity, positioning Bicycle Therapeutics at the forefront of innovation in treating cancer and other complex diseases. The company's therapeutic pipeline includes tumor-targeted and immune-activating treatments, alongside radiopharmaceutical applications, with a strategic vision to expand its reach through key partnerships.
How much funding has Bicycle raised?
Bicycle has raised a total of $645M across 3 funding rounds:
Debt
$40M
Other Financing Round
$50M
Share Placement
$555M
Debt (2020): $40M with participation from Hercules Capital
Other Financing Round (2020): $50M, investors not publicly disclosed
Share Placement (2024): $555M supported by Perceptive Advisors, EcoR1 Capital, RA Capital Management, Forbion, and Deep Track Capital
Key Investors in Bicycle
Perceptive Advisors
Perceptive Advisors is an investment firm focused on funding innovative healthcare and life sciences technologies, managing significant assets and aiming to support breakthroughs in biological and chemical discovery.
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund specializing in the biotech sector, committed to building long-term partnerships with entrepreneurs advancing therapeutic innovation.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, including those developing drugs and diagnostics, with a growing interest in climate technologies.
What's next for Bicycle?
The recent major enterprise-level funding and strategic investment indicate Bicycle Therapeutics is poised for significant expansion and advancement of its therapeutic candidates through clinical trials. This influx of capital will likely accelerate the development of its bicyclic peptide-based medicines, potentially leading to new treatment paradigms for oncology and other serious conditions. The company's focus on high specificity and binding affinity suggests a commitment to precision medicine, aiming to deliver more effective and targeted therapies to patients.
See full Bicycle company page
